Gilead Adjusts Planned Change in its Patient Assistance After HIV Community Pushes Back
Drug manufacturer Gilead has altered a planned change to its patient assistance program (PAP) for uninsured people living with HIV that would have been unworkable for some vulnerable patients, HIV/AIDS caregivers and activists say. The change also would have deprived 340B covered entities of savings on Gilead HIV products that help fund wrap-around services for these patients, they say.